Labcorp agrees to buy select BioReference Health assets for $722 million plus earnout
OPK•Labcorp agreed to acquire select BioReference Health assets from OPKO Health for $722 million in cash, with up to $150 million in additional earnout payments tied to 4Kscore test revenue. The acquired business is expected to generate about $250 million in revenue in its first year after closing.
1. Deal terms
Labcorp agreed to acquire select BioReference Health assets from OPKO Health for $722 million in cash, subject to closing revenue adjustments. The deal includes the 4Kscore prostate cancer test and up to $150 million in earnout payments tied to test revenue.
2. Business and closing
The acquired assets include clinical and specialty testing businesses and more than 80 additional patient service centers. The business is expected to generate approximately $250 million in revenue in the first year after closing; completion is subject to regulatory approvals and customary closing conditions.
